Ruggero Capra

Ruggero Capra

Auto-generated profile, based on publicly available information

Ruggero Capra

Multiple Sclerosis Centre, Spedali Civili di Brescia, Via Ciotti 154, 25018 Montichiari, Brescia, Italy

Research Focus & Metrics

Academic Career Length

14Years (2013-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 June 2020 in European Journal of Internal Medicine
Verified
Journal Article
Closed access
RCRuggero Capra
Ruggero Capra
NRNicola De Rossi
Nicola De Rossi
FMFlavia Mattioli
Flavia Mattioli
GRGiuseppe Romanelli
Giuseppe Romanelli
CSCristina Scarpazza
Cristina Scarpazza
SCStefania Cossi
Stefania Cossi

31 March 2020 in Neurotherapeutics
Verified
Journal Article
Closed access
PDF file
LPLuca Prosperini
Luca Prosperini
CMChiara Rosa Mancinelli
Chiara Rosa Mancinelli
CSClaudio Marcello Solaro
Claudio Marcello Solaro
Viviana NocitiViviana Nociti
Viviana Nociti
SHShalom Haggiag
Shalom Haggiag
CGClaudio Gasperini
Claudio Gasperini

21 March 2017 in Neurology
Verified
Journal Article
Closed access
PDF file
DLDoriana Landi
Doriana Landi
NRNicola De Rossi
Nicola De Rossi
SZSara Zagaglia
Sara Zagaglia
CSCristina Scarpazza
Cristina Scarpazza
LPLuca Prosperini
Luca Prosperini
Diego CentonzeDiego Centonze
Diego Centonze
Objective: To examine retrospectively the effects of plasmapheresis (PLEX) on the survival and clinical outcomes of patients with multiple sclerosis (MS) and natalizumab (NTZ)–associated progressive multifocal leukoencephalopathy (PML). Methods: The medical literature was searched for the terms natalizumab and progressive multifocal leukoencephalopathy. A total of 193 international and 34 Italian NTZ-PML cases were included. Clinical outcome was determined by comparing the patients9 clinical status at PML diagnosis with status after PML resolution. The effects on survival and clinical outcome of PLEX, sex, age, country, pre-PML Expanded Disability Status Scale score, NTZ infusion number, prior immunosuppressant exposure, PML symptoms, PML lesion location at diagnosis, CSF JC virus status and copies, additional PML treatments and steroids, and PML immune reconstitution inflammatory syndrome (IRIS) development were investigated with both univariate and multivariate analyses. Results: A total of 219 NTZ-PML cases were analyzed, and 184 (84%) underwent PLEX, which did not reduce the mortality risk or the likelihood of poor vs favorable outcomes. Country was predictive of mortality and poor outcome, while PML-IRIS development was predictive of poor outcome. Conclusions: PLEX did not improve the survival or clinical outcomes of Italian or international patients with MS and NTZ-PML, suggesting that this treatment should be performed cautiously in the future. Classification of evidence: This study provides Class III evidence that for patients with NTZ-PML, PLEX does not improve survival. The study lacks the statistical precision to exclude an important benefit or harm of PLEX.

10 October 2017 in Annals of Neurology
Verified
Journal Article
Closed access
PDF file
CSCristina Scarpazza
Cristina Scarpazza
LPLuca Prosperini
Luca Prosperini
NRNicola De Rossi
Nicola De Rossi
LMLucia Moiola
Lucia Moiola
MSMaria Pia Sormani
Maria Pia Sormani
OGon behalf of the Italian PML group
on behalf of the Italian PML group

8 August 2017 in Journal of NeuroVirology
Verified
Journal Article
Closed access
PDF file
LPLuca Prosperini
Luca Prosperini
CSCristina Scarpazza
Cristina Scarpazza
LILuisa Imberti
Luisa Imberti
CCCinzia Cordioli
Cinzia Cordioli
NRNicola De Rossi
Nicola De Rossi
RCRuggero Capra
Ruggero Capra

15 April 2020 in Journal of Neurology
Verified
Journal Article
Closed access
PDF file
FMFlavia Mattioli
Flavia Mattioli
FBF. Bellomi
F. Bellomi
CSC. Stampatori
C. Stampatori
SMS. Mariotto
S. Mariotto
SFS. Ferrari
S. Ferrari
RCR. Capra
R. Capra